ALK a Novel Lymphoma-associated Tumor Antigen for Vaccination Strategies
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (10) , 1675-1681
Abstract
The discovery of Tumor Associated Antigens (TAAs) demonstrated that tumor cells can be specifically recognized by the immune system raising the hypothesis that tumors express antigens that Cytotoxic T Lymphocytes (CTLs) can potentially attack. The identification of immunogenic epitopes led to their use as targets to mediate the specific clearance of neoplastic cells by TAA targeting strategies such as vaccination strategies. One of the critical issues in the development of efficient vaccination protocols is the identification of the appropriate TAAs. The TAA should be effective as a "tumor rejection antigen" able to induce an immune response that will affect tumor growth. A distinct pathologic entity characterized by the expression of the Anaplastic Lymphoma Kinase (ALK) protein and named "ALKoma" has recently emerged within the heterogeneous group of CD30+ Anaplastic Large Cell Lymphoma (ALCL). ALK is a receptor tyrosine kinase whose expression is normally restricted to a few scattered cells in the nervous system. Its pathological expression in lymphoma cells is due to a chromosomal translocation that leads to the formation of an ALK-derived oncogenic fusion proteins. ALK fusion proteins ectopically over-expressed and constitutively activated in lymphoid cells play a key role in the neoplastic transformation by the aberrant phosphorilation of intracellular substrates that likely contributes to the molecular pathogenesis of ALCL. The high level of ALK expression in lymphoma cells and its direct role in lymphomagenesis, combined with the fact that normal ALK is expressed at low levels in the immune privileged nervous system, makes ALK an ideal lymphoma-specific target for immunotherapy of ALK+ALCL.Keywords
This publication has 70 references indexed in Scilit:
- Designing HER2 vaccinesSeminars in Oncology, 2002
- Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell deathOncogene, 2002
- Cancer genetics and tumor antigens: time for a combined view?Genes, Chromosomes and Cancer, 2001
- Prognostic significance of p80 and visceral involvement in childhood CD30 anaplastic large cell lymphoma (ALCL)Medical and Pediatric Oncology, 2001
- Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90Blood, 2001
- Immune selection after antigen-specific immunotherapy of melanomaSurgery, 1999
- Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT)Bone Marrow Transplantation, 1999
- Tumor Eradication by Wild-type p53-specific Cytotoxic T LymphocytesJournal of Experimental Medicine, 1997
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's LymphomaScience, 1994
- Immunocytochemical Analysis of the Cellular Infiltrate in Primary Regressing and Non-Regressing Malignant MelanomaJournal of Investigative Dermatology, 1991